Biogen Inc.: Biogen Announces the Expiration Date Results of Its Private Exchange Offer
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) Biogen Inc. ( Biogen ) (Nasdaq: BIIB) today announced the expiration date results of its previously announced private offer to exchange (the Exchange Offer ) any and all of its outstanding 5.200% Senior Notes due 2045 (the Old Notes ), totaling $1.75 billion in aggregate principal amount, for a new series of 3.250% senior notes due 2051 to be issued by Biogen (the New Notes ) and cash on the terms and subject to conditions set forth in the Offering Memorandum dated February 4, 2021 (the Offering Memorandum ) and the accompanying eligibility letter (the Eligibility Letter ), Canadian beneficial holder form and notice of guaranteed delivery (collectively, the Exchange Offer Documents ).
Biogen Inc.: Biogen Announces the Expiration Date Results of Its Cash Tender Offer
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) Biogen Inc. ( Biogen ) (Nasdaq: BIIB) today announced the expiration date results of its previously announced offer to purchase for cash (the Cash Offer ) its outstanding 5.200% Senior Notes due 2045 (the Notes ), totaling $1.75 billion in aggregate principal amount, on the terms and subject to the conditions set forth in the Offer to Purchase dated February 4, 2021 (the Offer to Purchase ) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the Cash Offer Documents ).
Biogen Inc.: Biogen Announces the Pricing Terms of Its Private Exchange Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biogen Inc. ( Biogen ) (Nasdaq: BIIB) today announced the pricing terms of its previously announced private offer to exchange (the Exchange Offer ) any and all of its outstanding 5.200% Senior Notes due 2045 (the Old Notes ), totaling $1.75 billion in aggregate principal amount, for a new series of 3.250% senior notes due 2051 to be issued by Biogen (the New Notes ) and cash on the terms and subject to the conditions set forth in the Offering Memorandum dated February 4, 2021 (the Offering Memorandum ) and the accompanying eligibility letter (the Eligibility Letter ), Canadian beneficial holder form and notice of guaranteed delivery (collectively, the Exchange Offer Documents ).
On 2 December 2020, GardaWorld published an offer document (the Increased Offer Document ) setting out the terms of its increased cash offer, made through its wholly-owned subsidiary Fleming, to acquire the entire issued and to be issued share capital of G4S plc ( G4S ) (other than the G4S Shares already held by Fleming) (the CashOffer ). GardaWorld is considering its options and a further announcement will be made when appropriate. G4S Shareholders are strongly advised to take no action at this time. The Cash Offer, which otherwise remains subject to the terms and conditions set out in the Increased Offer Document (noting the no increase statement regarding the offer price is no longer in effect and has been set aside), is being extended and will remain open for acceptance until 1.00 p.m. (London time) on 6 March 2021.
Biogen Announces the Pricing Terms of its Cash Tender Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal amount, on the terms and subject to the conditions set forth in the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the “Cash Offer Documents”).